ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    VX15-809-115
Previous Study | Return to List | Next Study

Safety and Pharmacokinetic Study of Lumacaftor/Ivacaftor in Subjects Aged 2 Through 5 Years With Cystic Fibrosis, Homozygous for F508del

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02797132
Recruitment Status : Completed
First Posted : June 13, 2016
Results First Posted : October 30, 2018
Last Update Posted : October 30, 2018
Sponsor:
Information provided by (Responsible Party):
Vertex Pharmaceuticals Incorporated

Brief Summary:
This is a Phase 3, 2-part (Part A and Part B), open-label, multicenter study evaluating the pharmacokinetics (PK), safety, tolerability, and pharmacodynamics (PD) of multiple doses of lumacaftor/ivacaftor (LUM/IVA) in subjects 2 through 5 years of age (inclusive) with cystic fibrosis (CF), homozygous for F508del. Subjects who participate in Part A may participate in Part B, if they meet the eligibility criteria.

Condition or disease Intervention/treatment Phase
Cystic Fibrosis Drug: LUM/IVA Phase 3

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 62 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 3, 2-Part, Open-label Study to Evaluate the Safety and Pharmacokinetics of Lumacaftor/Ivacaftor Combination Therapy in Subjects Aged 2 Through 5 Years With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation
Actual Study Start Date : May 2016
Actual Primary Completion Date : September 2017
Actual Study Completion Date : September 2017

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Cystic Fibrosis
Drug Information available for: Ivacaftor

Arm Intervention/treatment
Experimental: Lumacaftor/Ivacaftor (LUM/IVA)

Part A (<14 kg): Participants weighing less than (<) 14 kilograms (kg) at screening received LUM 100 milligram (mg)/IVA 125 mg fixed-dose combination every 12 hours for 15 days in Part A.

Part A (>=14 kg): Participants weighing greater than or equal to (>=) 14 kg at screening received LUM 150 mg/IVA 188 mg fixed-dose combination every 12 hours for 15 days in Part A.

Part B (<14 kg): Participants weighing <14 kg at screening received LUM 100 mg/IVA 125 mg fixed-dose combination every 12 hours for 24 weeks in Part B.

Part B (>=14 kg): Participants weighing >=14 kg at screening received LUM 150 mg/IVA 188 mg fixed-dose combination every 12 hours for 24 weeks in Part B.

Drug: LUM/IVA
Other Names:
  • Orkambi
  • VX-809+VX-770




Primary Outcome Measures :
  1. Part A: Pre-dose Concentration (Ctrough) of LUM and IVA [ Time Frame: Day 15 ]
  2. Part B: Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) [ Time Frame: Day 1 up to Week 26 ]

Secondary Outcome Measures :
  1. Part A: Pre-dose Concentration (Ctrough) of LUM and IVA Metabolites [ Time Frame: Day 15 ]
  2. Part A: Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) [ Time Frame: Day 1 up to Day 25 ]
  3. Part B: Absolute Change From Baseline in Sweat Chloride at Week 24 [ Time Frame: Baseline, Week 24 ]
    Sweat samples were collected using an approved collection device.

  4. Part B: Absolute Change From Baseline in Body Mass Index (BMI) at Week 24 [ Time Frame: Baseline, Week 24 ]
    BMI was defined as weight in kilograms (kg) divided by height in square meter (m^2).

  5. Part B: Absolute Change From Baseline in Body Mass Index (BMI) For-Age Z-Score at Week 24 [ Time Frame: Baseline, Week 24 ]
    BMI was defined as weight in kg divided by height in m^2. z-score is a statistical measure to describe whether a mean was above or below the standard. BMI, adjusted for age and sex, was analyzed as BMI-for-age z-score (BMI z-score).

  6. Part B: Absolute Change From Baseline in Weight at Week 24 [ Time Frame: Baseline, Week 24 ]
  7. Part B: Absolute Change From Baseline in Weight-for-age Z-Score at Week 24 [ Time Frame: Baseline, Week 24 ]
    z-score is a statistical measure to describe whether a mean was above or below the standard. Weight, adjusted for age and sex, was analyzed as weight-for-age z-score (Weight z-score).

  8. Part B: Absolute Change From Baseline in Stature (Height) at Week 24 [ Time Frame: Baseline, Week 24 ]
  9. Part B: Absolute Change From Baseline in Stature-for-Age Z-Score [ Time Frame: Baseline, Week 24 ]
    z-score is a statistical measure to describe whether a mean was above or below the standard. Stature (height), adjusted for age and sex, was analyzed as Stature-for-age z-score (Stature z-score).

  10. Part B: Number of Pulmonary Exacerbations [ Time Frame: Through Week 24 ]
    Pulmonary exacerbation was defined as new or changed treatment with oral, inhaled, or intravenous antibiotics and fulfillment of pre-specified protocol defined criteria.

  11. Part B: Number of Participants With at Least One Pulmonary Exacerbation Pulmonary Exacerbation Through Week 24 [ Time Frame: Through Week 24 ]
    Pulmonary exacerbation was defined as new or changed treatment with oral, inhaled, or intravenous antibiotics and fulfillment of pre-specified protocol defined criteria. Time to event data was not collected and instead, number of participants with first event were collected and are reported. Time-to-first pulmonary exacerbation was planned to be estimated using Kaplan-Meier (KM) estimates. However, due to less than 50% of events, time-to-first event data was not estimated. Instead, number of participants with at least one pulmonary exacerbation event were collected and are reported.

  12. Part B: Number of Cystic Fibrosis (CF)-Related Hospitalizations [ Time Frame: Through Week 24 ]
  13. Part B: Absolute Change From Baseline in Fecal Elastase-1 (FE-1) Levels at Week 24 [ Time Frame: Baseline, Week 24 ]
  14. Part B: Absolute Change From Baseline in Serum Levels of Immunoreactive Trypsinogen (IRT) Through Week 24 [ Time Frame: Baseline, Through Week 24 ]
  15. Part B: Number of Participants With Microbiology Culture Status (Positive or Negative) at Week 24 [ Time Frame: Baseline and Week 24 ]
    Following microbial tests were performed: Burkholderia, Methicillin Resistant Staphylococcus Aureus (MRSA), Methicillin Susceptible Staphylococcus Aureus (MSSA), Pseudomonas Aeruginosa Mucoid (P. Aeruginosa Mucoid), P. Aeruginosa Non-Mucoid, P. Aeruginosa Small Colony Variant and Stenotrophomonas Maltophilia.

  16. Part B: Absolute Change From Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) at Week 24 [ Time Frame: Baseline, Week 24 ]
    FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration.

  17. Part B: Absolute Change in Sweat Chloride From Week 24 at Week 26 [ Time Frame: Week 24, Week 26 ]
    Sweat samples were collected using an approved collection device.

  18. Part B: Acceptability/Palatability of LUM/IVA Granules Measured Using Hedonic Scale [ Time Frame: Day 1 ]
    The acceptability and palatability of LUM/IVA granules was assessed by a visual analog scale that incorporates a 5 point facial hedonic scale (Liked it Very Much, Liked it a Little, Not sure, Disliked it a Little, Disliked it Very Much). The assessment was conducted in 2 steps: assessment of approved food/liquid (Evaluation 1), and assessment of approved food/liquid with LUM/IVA granules (Evaluation 2).

  19. Part B: Absolute Change From Baseline in Lung Clearance Index (LCI) 2.5 at Week 24 [ Time Frame: Baseline, Week 24 ]
    Lung clearance index (LCI) is a measure of ventilation inhomogeneity that is derived from a multiple breath washout test using Nitrogen (N2). LCI 2.5 represents the number of lung turnovers required to reduce the end tidal inert gas concentration to 1/40th of its starting value.

  20. Part B: Absolute Change From Baseline in Lung Clearance Index (LCI) 5.0 at Week 24 [ Time Frame: Baseline, Week 24 ]
    LCI is a measure of ventilation inhomogeneity that is derived from a multiple breath washout test using Nitrogen (N2). LCI 5.0 represents the number of lung turnovers required to reduce the end tidal inert gas concentration to 1/20th of its starting value.

  21. Part B: Pre-dose Concentration (Ctrough) of LUM and IVA and Its Metabolites [ Time Frame: Week 24 ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   2 Years to 5 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Subjects who weigh ≥8 kilogram (kg) without shoes and wearing light clothing at the Screening Visit
  • Subjects with confirmed diagnosis of CF at the Screening Visit
  • Subjects who are homozygous for the F508del-cystic fibrosis transmembrane conductance regulator (CFTR) mutation

Exclusion Criteria:

  • Any clinically significant laboratory abnormalities at the Screening Visit that would interfere with the study assessments or pose an undue risk for the subject
  • An acute upper or lower respiratory infection, pulmonary exacerbation, or changes in therapy (including antibiotics) for pulmonary disease within 28 days before Day 1
  • A standard 12-lead ECG demonstrating QTc >450 millisecond (msec) at the Screening Visit.
  • History of solid organ or hematological transplantation.
  • Ongoing or prior participation in an investigational drug study (including studies investigating LUM and/or IVA) within 30 days of the Screening Visit.
  • History of cataract/lens opacity or evidence of cataract/lens opacity determined to be clinically significant by a licensed ophthalmologist during the ophthalmologic examination at the Screening Visit

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02797132


  Show 20 Study Locations
Sponsors and Collaborators
Vertex Pharmaceuticals Incorporated
  Study Documents (Full-Text)

Documents provided by Vertex Pharmaceuticals Incorporated:
Study Protocol  [PDF] April 13, 2017
Statistical Analysis Plan  [PDF] September 23, 2016


Responsible Party: Vertex Pharmaceuticals Incorporated
ClinicalTrials.gov Identifier: NCT02797132     History of Changes
Other Study ID Numbers: VX15-809-115
2016-001004-33 ( EudraCT Number )
First Posted: June 13, 2016    Key Record Dates
Results First Posted: October 30, 2018
Last Update Posted: October 30, 2018
Last Verified: September 2018

Keywords provided by Vertex Pharmaceuticals Incorporated:
CF

Additional relevant MeSH terms:
Fibrosis
Cystic Fibrosis
Pathologic Processes
Pancreatic Diseases
Digestive System Diseases
Lung Diseases
Respiratory Tract Diseases
Genetic Diseases, Inborn
Infant, Newborn, Diseases
Ivacaftor
Chloride Channel Agonists
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action